Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Taltz, Lilly's immunosuppressant, reported revenue of $3.3 billion last year, 18% higher than the year-ago period. Eli Lilly isn't just a diabetes or a weight loss company. These products -- and ...

And finally, we have both Taltz and Humalog ... we would see that Eli Lilly is more expensive than any of these businesses. On an adjusted basis, analysts believe that earnings per share will ...

and Taltz and Olumiant for immunology. Having examined the options trading patterns of Eli Lilly, our attention now turns directly to the company. This shift allows us to delve into its present ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...

Eli Lilly is a drug firm with a focus on neuroscience ... and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. With a volume of 1,063,466, the price of LLY is up 4.39% at ...

Eli Lilly (LLY 0.21%) is a leading pharmaceutical company. It has developed several blockbuster products, including Trulicity (type 2 diabetes), Taltz (plaque psoriasis), and Jardiance (blood sugar).

Eli Lilly is diversified beyond obesity and diabetes. For instance, Verzenio (breast cancer) grew 36% year-over-year to reach $1.555 billion in Q4. In addition, Taltz (plaque psoriasis ...

Last year, its sales soared by 37% year over year to $5.3 billion. Taltz, Lilly's immunosuppressant, reported revenue of $3.3 billion last year, 18% higher than the year-ago period. Eli Lilly isn't ...

Eli Lilly, Vertex, Meta Platforms ... Older medicines, such as cancer medicine Verzenio and immunosuppressant Taltz, continue to help drive top-line growth. And amid the strong financial results ...